靶向蛋白质降解的全球市场（2023-2030）：按用途、技术（PROTAC、LYTAC）、治疗领域和适应症分类的规模、份额、增长分析和预测

预测期内，全球靶向蛋白质降解市场规模将以 10.2% 的年复合成长率增长，从 2021 年的 1.0331 亿美元和 2022 年的 1.1385 亿美元增长到 2030 年的 2.4761 亿美元，预计将增长到

靶向蛋白水解是一种相对较新的药物开发策略，由于它使用微小化合物来特异性破坏致病蛋白质，因此越来越受欢迎。据说这种方法在药物开发方面比传统方法具有许多优势。其优点包括独特的作用方式、联合治疗潜力、广泛的适用性、改进的选择性和高耐久性。

对许多疾病更有效的治疗方法的需求不断增长，是目标蛋白质降解市场的驱动因素之一。由于它们对患者健康和生活质量具有重大影响，因此对能够解决癌症、遗传异常和自身免疫性疾病等疾病根本原因的药物的需求不断增长。降解目标蛋白以优先考虑致病蛋白可能会带来更有效且副作用更少的治疗方法。这种策略使得製造能够选择性攻击病原体蛋白质同时保护健康细胞和组织的药物成为可能。

对口服药物开发的日益关注是靶向蛋白水解市场的主要发展之一。对方便、合规和患者友好的药物日益增长的需求正在推动这一发展。与註射和静脉注射等其他给药方法相比，口服药物具有显着的优势，因为它们可以方便地在家中服用，不需要患者前往医院或诊所接受治疗。多家製药公司投入巨资研发可分解目标蛋白质的口服药物，从而生产出可以穿过消化系统到达体内目标器官的药物。

在本报告中，我们研究了全球靶向蛋白质降解市场，并提供了市场概述、市场各种影响因素分析、技术和创新趋势、法律和监管环境、市场规模趋势和预测以及细分细分市场和区域，总结了主要公司的细分、竞争格局、概况等。

目录

执行摘要

调查方法

母公司市场分析

• 市场概况
• 市场规模
• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务

关键市场洞察

• 技术分析
• 价格分析
• 供应链分析
• 价值链分析
• 市场生态系统
• 知识产权分析
• 贸易分析
• 启动分析
• 原材料分析
• 创新矩阵
• 管道产品分析
• 宏观经济指标
• 主要投资分析
• 关键成功因素
• 竞争程度

市场动态及预测

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 监管状况
• 波特的分析
• Skyquest 对未来颠覆的特别见解

全球目标蛋白降解市场（按用途）

• 市场概况
• 小分子药物发现
• 蛋白质发现
• 研究
• 其他的

全球目标蛋白降解市场（按技术）

• 市场概况
• PROTACs
• LYTACs
• SNIPERs
• 分子胶
• 其他的

全球目标蛋白质降解市场：按治疗领域

• 市场概况
• 瘤
• 免疫
• 遗传性疾病/其他

全球目标蛋白降解市场：按适应症分类

• 市场概况
• 乳腺癌
• 肺癌
• 白血病
• 实体瘤/其他

全球目标蛋白质降解市场（按地区）

• 市场概况
• 北美
• 欧洲
• 亚太地区
• 拉美
• 中东/非洲

竞争格局

• 前5名企业对比
• 主要企业市场定位
• 各大公司的招聘策略
• 关键成功策略
• 近期市场活动
• 主要参与者的市场份额

主要公司简介

• Arvinas, Inc.
• C4 Therapeutics
• Kymera Therapeutics
• Nurix Therapeutics
• Dewpoint Therapeutics
• PROTACs Therapeutics
• Amgen Inc.
• AstraZeneca
• Bayer AG
• Celgene Corporation
• Genentech, Inc.
• Gilead Sciences, Inc.
• Novartis AG
• Sanofi SA
• Takeda Pharmaceutical Company Limited.

Global Targeted Protein Degradation Market size was valued at USD 103.31 million in 2021 and is poised to grow from USD 113.85 million in 2022 to USD 247.61 million by 2030, growing at a CAGR of 10.2% in the forecast period (2023-2030).

Since it is a relatively recent strategy for medication development and uses tiny compounds to specifically destroy disease-causing proteins, targeted protein degradation is growing in popularity. This method is said to provide a number of benefits over more conventional approaches to drug development. These benefits include unique method of action, potential for combination therapy, broad applicability, improved selectivity, and higher durability. Top-down and bottom-up approaches were used to estimate and validate the size of Targeted Protein Degradation and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

Applications, technologies, therapeutic areas, indications, and geographical regions are used to segment the global market for targeted protein degradation. The market is divided into Small Molecule Drug Discovery, Protein Discovery, Research Applications, and Other End Use Applications. The market has been divided into PROTACs (Proteolysis-Targeting Chimeras), LYTACs (Lysosome-Targeting Chimeras), SNIPERs (Specific and Non-genetic IAP-dependent Protein ERasers), molecular glues, and other categories based on technology. The market is divided into oncology, immunology, genetic disorders, and other diseases based on therapeutic area. According to preliminary data, the market is divided into categories for solid tumors, leukemia, breast cancer, and lung cancer. North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America are the different geographic segments of the market.

Driver

Increasing Demand for Effective Cancer Treatment to Boost Market Growth

The growing demand for more efficient treatments for a number of disorders is one of the reasons propelling the market for targeted protein degradation. There is a rising demand for medicines that can address the underlying causes of diseases like cancer, genetic abnormalities, and autoimmune diseases because they have a substantial influence on patients' health and quality of life. The potential for preferentially focusing on disease-causing proteins through targeted protein breakdown could lead to more effective treatments with fewer adverse effects. This strategy makes it possible to create medications that selectively attack the pathogen-causing proteins while protecting healthy cells and tissues.

Restraints

Complexity of Targeted Protein Degradation to Hinder Market Growth

The complexity of this industry is one of the main obstacles facing the targeted protein degradation market. This strategy necessitates a thorough knowledge of the structure and purpose of proteins in addition to sophisticated skills in drug research and design. This technique can make it difficult and time-consuming to develop novel therapeutics, which could impede the field's advancement. Developing medications that can selectively degrade particular proteins within cells is a relatively new and complicated field known as targeted protein degradation. These medications are made to benefit from the cell's built-in machinery for protein breakdown, which enables them to specifically target disease-causing proteins while sparing healthy cells.

Market Trend

The increased focus on oral medication development is one of the market's major developments in targeted protein degradation. The rising need for more patient-friendly medicines that provide better convenience and compliance is what is driving this development. Because they may be conveniently administered at home and don't require patients to travel to hospitals or clinics for treatment, oral medications offer a substantial benefit over other drug delivery methods like injections and infusions. Several pharmaceutical companies are making significant investments in the research and development of oral medications for targeted protein breakdown to counter this tendency. Drugs that can make it past the digestive system and into the body's target organs are being developed.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Targeted Protein Degradation Market by Application

• Market Overview
• Small Molecule drug discovery
• protein discovery
• research applications
• and others

Global Targeted Protein Degradation Market by Technology

• Market Overview
• PROTACs (Proteolysis-Targeting Chimeras)
• LYTACs (Lysosome-Targeting Chimeras)
• and SNIPERs (Specific and Non-genetic IAP-dependent Protein ERasers)
• Molecular glues
• and others

Global Targeted Protein Degradation Market by Therapeutic area

• Market Overview
• Oncology
• immunology
• genetic disorder and other diseases

Global Targeted Protein Degradation Market by Indication

• Market Overview
• Breast cancer
• lung cancer
• leukemia
• solid tumors and others

Global Targeted Protein Degradation Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Arvinas, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• C4 Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kymera Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nurix Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dewpoint Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PROTACs Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments